[영어] - [한영]

등록자 : 관리자

업데이트 : 2020. 5. 31. 오전 7:10:05

2005허7545

Korean Patent Court Decision No. 2005HEO7545 (October 11, 2006) stated the following:

A use invention of a medicine must clearly describe the medicinal use of a specific material in terms of the to-be-treated diseases or pharmacological effects. To do so, (i) the use invention must describe well-known individual or specific disease names, (ii) describe a well-known comprehensive concept (e.g. antipyreptic) encompassing such diseases, (iii) if the correlation between the activation mechanism and the to-be-treated diseases is not well-known, describe the activation mechanism as functional expressions, or (iv) for diseases or a group of relevant diseases which are not known before the filing of the patent application, describe the specific pathological definition, diagnosis methods, pathological mechanism and pharmacological mechanism in the specification so that such to-be-treated diseases can be defined. Based on these requirements, since the claim for “a composition for the treatment of nitric oxide overproduction associated with septic shock, regional ischemia, and so on” may be interpreted ambiguously, and the diseases to be treated are unclear and the relationship between all listed diseases and the nitric oxide overproduction is not established nor is it established whether the low blood pressure or multiple organ dysfunction syndrome is induced by the medium of nitric oxide overproduction, it is not considered that the medicinal use is clearly described in terms of to-be-treated diseases or pharmacological effects.